JP2005312446A5 - - Google Patents

Info

Publication number

JP2005312446A5

JP2005312446A5 JP2005105155A JP2005105155A JP2005312446A5 JP 2005312446 A5 JP2005312446 A5 JP 2005312446A5 JP 2005105155 A JP2005105155 A JP 2005105155A JP 2005105155 A JP2005105155 A JP 2005105155A JP 2005312446 A5 JP2005312446 A5 JP 2005312446A5

Authority

JP

Japan

Prior art keywords

gold

protein

domain

binding

antibody

Prior art date

2005-03-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000010931 gold Substances 0.000 claims description 327
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 320
• 229910052737 gold Inorganic materials 0.000 claims description 318
• 108090000623 proteins and genes Proteins 0.000 claims description 308
• 102000004169 proteins and genes Human genes 0.000 claims description 263
• 239000000758 substrate Substances 0.000 claims description 127
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 99
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
• 229920001184 polypeptide Polymers 0.000 claims description 83
• 239000013076 target substance Substances 0.000 claims description 74
• 150000001413 amino acids Chemical class 0.000 claims description 54
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
• 238000009739 binding Methods 0.000 description 233
• 235000018102 proteins Nutrition 0.000 description 216
• 239000000243 solution Substances 0.000 description 172
• 238000000034 method Methods 0.000 description 117
• 239000000126 substance Substances 0.000 description 86
• 210000004027 cell Anatomy 0.000 description 74
• 102000014914 Carrier Proteins Human genes 0.000 description 68
• 108091008324 binding proteins Proteins 0.000 description 68
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 61
• 239000007983 Tris buffer Substances 0.000 description 46
• 238000000746 purification Methods 0.000 description 46
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 45
• 229940024606 amino acid Drugs 0.000 description 42
• 108091007433 antigens Proteins 0.000 description 42
• 102000036639 antigens Human genes 0.000 description 42
• 239000012634 fragment Substances 0.000 description 42
• 150000007523 nucleic acids Chemical class 0.000 description 42
• 239000000427 antigen Substances 0.000 description 40
• 239000013604 expression vector Substances 0.000 description 40
• 238000002372 labelling Methods 0.000 description 39
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 37
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 37
• 102000039446 nucleic acids Human genes 0.000 description 36
• 108020004707 nucleic acids Proteins 0.000 description 36
• 239000013612 plasmid Substances 0.000 description 35
• 239000000523 sample Substances 0.000 description 35
• 230000006870 function Effects 0.000 description 31
• 238000002360 preparation method Methods 0.000 description 31
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 30
• 229960000789 guanidine hydrochloride Drugs 0.000 description 28
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 28
• 238000000502 dialysis Methods 0.000 description 26
• 239000010419 fine particle Substances 0.000 description 26
• 238000005259 measurement Methods 0.000 description 26
• 239000013598 vector Substances 0.000 description 25
• 238000011156 evaluation Methods 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 23
• 239000003550 marker Substances 0.000 description 23
• 229910052751 metal Inorganic materials 0.000 description 23
• 239000002184 metal Substances 0.000 description 23
• 239000012228 culture supernatant Substances 0.000 description 22
• 238000001514 detection method Methods 0.000 description 22
• 239000000463 material Substances 0.000 description 22
• 108091008146 restriction endonucleases Proteins 0.000 description 22
• 239000006228 supernatant Substances 0.000 description 22
• 241000282414 Homo sapiens Species 0.000 description 21
• -1 latex Chemical compound 0.000 description 21
• 238000004519 manufacturing process Methods 0.000 description 21
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
• 125000005647 linker group Chemical group 0.000 description 19
• 108020004414 DNA Proteins 0.000 description 18
• 102000053602 DNA Human genes 0.000 description 18
• 108010076504 Protein Sorting Signals Proteins 0.000 description 18
• 241000588724 Escherichia coli Species 0.000 description 17
• 230000000694 effects Effects 0.000 description 17
• 239000008187 granular material Substances 0.000 description 17
• 238000010586 diagram Methods 0.000 description 16
• 239000011521 glass Substances 0.000 description 16
• 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 15
• 101150040383 pel2 gene Proteins 0.000 description 15
• 101150050446 pelB gene Proteins 0.000 description 15
• 238000003756 stirring Methods 0.000 description 14
• 238000005406 washing Methods 0.000 description 14
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 13
• 239000013522 chelant Substances 0.000 description 13
• 239000002131 composite material Substances 0.000 description 13
• 108020001507 fusion proteins Proteins 0.000 description 13
• 102000037865 fusion proteins Human genes 0.000 description 13
• 239000007788 liquid Substances 0.000 description 13
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 13
• 201000002528 pancreatic cancer Diseases 0.000 description 13
• 208000008443 pancreatic carcinoma Diseases 0.000 description 13
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 206010033128 Ovarian cancer Diseases 0.000 description 12
• 238000010790 dilution Methods 0.000 description 12
• 239000012895 dilution Substances 0.000 description 12
• 239000000203 mixture Substances 0.000 description 12
• 239000000123 paper Substances 0.000 description 12
• 206010009944 Colon cancer Diseases 0.000 description 11
• 206010061535 Ovarian neoplasm Diseases 0.000 description 11
• 208000005718 Stomach Neoplasms Diseases 0.000 description 11
• 210000003719 b-lymphocyte Anatomy 0.000 description 11
• 238000005119 centrifugation Methods 0.000 description 11
• 238000010828 elution Methods 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 206010017758 gastric cancer Diseases 0.000 description 11
• 239000000499 gel Substances 0.000 description 11
• 239000002244 precipitate Substances 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 230000028327 secretion Effects 0.000 description 11
• 239000004065 semiconductor Substances 0.000 description 11
• 201000011549 stomach cancer Diseases 0.000 description 11
• 230000009466 transformation Effects 0.000 description 11
• 206010006187 Breast cancer Diseases 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 229920001213 Polysorbate 20 Polymers 0.000 description 10
• 230000001580 bacterial effect Effects 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 208000029742 colonic neoplasm Diseases 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• 238000002965 ELISA Methods 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 201000011510 cancer Diseases 0.000 description 9
• 230000008859 change Effects 0.000 description 9
• 238000010353 genetic engineering Methods 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 238000004091 panning Methods 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 238000012163 sequencing technique Methods 0.000 description 9
• 235000000346 sugar Nutrition 0.000 description 9
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
• PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
• 201000009036 biliary tract cancer Diseases 0.000 description 8
• 208000020790 biliary tract neoplasm Diseases 0.000 description 8
• 239000013613 expression plasmid Substances 0.000 description 8
• 239000000284 extract Substances 0.000 description 8
• 125000000524 functional group Chemical group 0.000 description 8
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
• 201000005202 lung cancer Diseases 0.000 description 8
• 208000020816 lung neoplasm Diseases 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• 101710132601 Capsid protein Proteins 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 125000003277 amino group Chemical group 0.000 description 7
• 230000003321 amplification Effects 0.000 description 7
• 239000012620 biological material Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000000052 comparative effect Effects 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 7
• 238000012790 confirmation Methods 0.000 description 7
• 238000004132 cross linking Methods 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• 239000010408 film Substances 0.000 description 7
• 230000004927 fusion Effects 0.000 description 7
• 238000003317 immunochromatography Methods 0.000 description 7
• 238000003199 nucleic acid amplification method Methods 0.000 description 7
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 230000035939 shock Effects 0.000 description 7
• 229910052710 silicon Inorganic materials 0.000 description 7
• 239000010703 silicon Substances 0.000 description 7
• 229910052709 silver Inorganic materials 0.000 description 7
• 238000001179 sorption measurement Methods 0.000 description 7
• 230000014616 translation Effects 0.000 description 7
• 101710094648 Coat protein Proteins 0.000 description 6
• 108010053070 Glutathione Disulfide Proteins 0.000 description 6
• 108090000288 Glycoproteins Proteins 0.000 description 6
• 102000003886 Glycoproteins Human genes 0.000 description 6
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 6
• 101710125418 Major capsid protein Proteins 0.000 description 6
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
• 101710141454 Nucleoprotein Proteins 0.000 description 6
• 101710083689 Probable capsid protein Proteins 0.000 description 6
• 239000004365 Protease Substances 0.000 description 6
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
• 229960002685 biotin Drugs 0.000 description 6
• 235000020958 biotin Nutrition 0.000 description 6
• 239000011616 biotin Substances 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 210000000805 cytoplasm Anatomy 0.000 description 6
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 230000000813 microbial effect Effects 0.000 description 6
• 239000011859 microparticle Substances 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 210000004976 peripheral blood cell Anatomy 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• 239000004332 silver Substances 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 239000010409 thin film Substances 0.000 description 6
• 229920000936 Agarose Polymers 0.000 description 5
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
• 108091005804 Peptidases Proteins 0.000 description 5
• 102000035195 Peptidases Human genes 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 238000007385 chemical modification Methods 0.000 description 5
• 238000001962 electrophoresis Methods 0.000 description 5
• 238000006911 enzymatic reaction Methods 0.000 description 5
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
• 230000003100 immobilizing effect Effects 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
• 229940124280 l-arginine Drugs 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 238000002823 phage display Methods 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 5
• 238000011144 upstream manufacturing Methods 0.000 description 5
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
• 102000004420 Creatine Kinase Human genes 0.000 description 4
• 108010042126 Creatine kinase Proteins 0.000 description 4
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
• 108010024636 Glutathione Proteins 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
• 102000057297 Pepsin A Human genes 0.000 description 4
• 108090000284 Pepsin A Proteins 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 208000035415 Reinfection Diseases 0.000 description 4
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
• 206010000891 acute myocardial infarction Diseases 0.000 description 4
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
• 229960000723 ampicillin Drugs 0.000 description 4
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
• 238000004140 cleaning Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 201000004101 esophageal cancer Diseases 0.000 description 4
• 230000001747 exhibiting effect Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 229960003180 glutathione Drugs 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 229940111202 pepsin Drugs 0.000 description 4
• 229910052697 platinum Inorganic materials 0.000 description 4
• 239000004417 polycarbonate Substances 0.000 description 4
• 229920000139 polyethylene terephthalate Polymers 0.000 description 4
• 239000005020 polyethylene terephthalate Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000001243 protein synthesis Methods 0.000 description 4
• 210000002027 skeletal muscle Anatomy 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 108010087967 type I signal peptidase Proteins 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 3
• 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241001524679 Escherichia virus M13 Species 0.000 description 3
• 108010003471 Fetal Proteins Proteins 0.000 description 3
• 102000004641 Fetal Proteins Human genes 0.000 description 3
• 102000005720 Glutathione transferase Human genes 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 108090000526 Papain Proteins 0.000 description 3
• 239000004793 Polystyrene Substances 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• 229920005654 Sephadex Polymers 0.000 description 3
• 239000012507 Sephadex™ Substances 0.000 description 3
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 description 3
• 239000008272 agar Substances 0.000 description 3
• 230000008033 biological extinction Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 239000004202 carbamide Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 201000006662 cervical adenocarcinoma Diseases 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 239000000470 constituent Substances 0.000 description 3
• 239000000385 dialysis solution Substances 0.000 description 3
• 210000004700 fetal blood Anatomy 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 229930027917 kanamycin Natural products 0.000 description 3
• 229960000318 kanamycin Drugs 0.000 description 3
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
• 229930182823 kanamycin A Natural products 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 229910044991 metal oxide Inorganic materials 0.000 description 3
• 150000004706 metal oxides Chemical class 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 229910052759 nickel Inorganic materials 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 239000011368 organic material Substances 0.000 description 3
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 3
• 235000019834 papain Nutrition 0.000 description 3
• 229940055729 papain Drugs 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 229920003023 plastic Polymers 0.000 description 3
• 239000004033 plastic Substances 0.000 description 3
• 229920000515 polycarbonate Polymers 0.000 description 3
• 239000002861 polymer material Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 235000019419 proteases Nutrition 0.000 description 3
• 239000012460 protein solution Substances 0.000 description 3
• 230000008707 rearrangement Effects 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 201000001275 rectum cancer Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 239000012146 running buffer Substances 0.000 description 3
• 239000012488 sample solution Substances 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 229910052814 silicon oxide Inorganic materials 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 210000004989 spleen cell Anatomy 0.000 description 3
• 239000012134 supernatant fraction Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 206010046766 uterine cancer Diseases 0.000 description 3
• 238000007740 vapor deposition Methods 0.000 description 3
• 239000011787 zinc oxide Substances 0.000 description 3
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• UAJRSHJHFRVGMG-UHFFFAOYSA-N 1-ethenyl-4-methoxybenzene Chemical compound COC1=CC=C(C=C)C=C1 UAJRSHJHFRVGMG-UHFFFAOYSA-N 0.000 description 2
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
• 206010048998 Acute phase reaction Diseases 0.000 description 2
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
• IRIAEXORFWYRCZ-UHFFFAOYSA-N Butylbenzyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 description 2
• SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
• 108010074051 C-Reactive Protein Proteins 0.000 description 2
• 102100032752 C-reactive protein Human genes 0.000 description 2
• XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
• 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 201000001342 Fallopian tube cancer Diseases 0.000 description 2
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 229910001218 Gallium arsenide Inorganic materials 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 108090001090 Lectins Proteins 0.000 description 2
• 102000004856 Lectins Human genes 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 238000009004 PCR Kit Methods 0.000 description 2
• 108010047320 Pepsinogen A Proteins 0.000 description 2
• 241000235648 Pichia Species 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 102100040756 Rhodopsin Human genes 0.000 description 2
• 108090000820 Rhodopsin Proteins 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 102000054727 Serum Amyloid A Human genes 0.000 description 2
• 101710190759 Serum amyloid A protein Proteins 0.000 description 2
• 229910004298 SiO 2 Inorganic materials 0.000 description 2
• 229910006404 SnO 2 Inorganic materials 0.000 description 2
• 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 2
• 208000007107 Stomach Ulcer Diseases 0.000 description 2
• 108010079337 Tissue Polypeptide Antigen Proteins 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 241000209140 Triticum Species 0.000 description 2
• 235000021307 Triticum Nutrition 0.000 description 2
• 108010084455 Zeocin Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
• 210000002798 bone marrow cell Anatomy 0.000 description 2
• 229940041514 candida albicans extract Drugs 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
• 238000010382 chemical cross-linking Methods 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 239000003398 denaturant Substances 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000004205 dimethyl polysiloxane Substances 0.000 description 2
• IPKKHRVROFYTEK-UHFFFAOYSA-N dipentyl phthalate Chemical compound CCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCC IPKKHRVROFYTEK-UHFFFAOYSA-N 0.000 description 2
• MQHNKCZKNAJROC-UHFFFAOYSA-N dipropyl phthalate Chemical compound CCCOC(=O)C1=CC=CC=C1C(=O)OCCC MQHNKCZKNAJROC-UHFFFAOYSA-N 0.000 description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 201000003908 endometrial adenocarcinoma Diseases 0.000 description 2
• 208000029382 endometrium adenocarcinoma Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
• NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 229910003472 fullerene Inorganic materials 0.000 description 2
• 229920001002 functional polymer Polymers 0.000 description 2
• 201000005917 gastric ulcer Diseases 0.000 description 2
• 229910052595 hematite Inorganic materials 0.000 description 2
• 239000011019 hematite Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 108010014723 immunosuppressive acidic protein Proteins 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 2
• SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
• ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 239000002523 lectin Substances 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 239000011259 mixed solution Substances 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 229920000620 organic polymer Polymers 0.000 description 2
• 210000002741 palatine tonsil Anatomy 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 238000013492 plasmid preparation Methods 0.000 description 2
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 239000004800 polyvinyl chloride Substances 0.000 description 2
• 229920000915 polyvinyl chloride Polymers 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 210000001995 reticulocyte Anatomy 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 238000005063 solubilization Methods 0.000 description 2
• 230000007928 solubilization Effects 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 2
• 229960002317 succinimide Drugs 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 239000012137 tryptone Substances 0.000 description 2
• 239000000439 tumor marker Substances 0.000 description 2
• KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical compound C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 2
• SNOYUTZWILESAI-UHFFFAOYSA-N vinyl isopropyl ketone Natural products CC(C)C(=O)C=C SNOYUTZWILESAI-UHFFFAOYSA-N 0.000 description 2
• 239000012138 yeast extract Substances 0.000 description 2
• 229910000859 α-Fe Inorganic materials 0.000 description 2
• ZXFXBSWRVIQKOD-AQTZKLSLSA-N (1R,2R,3S,5S,6R,7S,8S)-1,6,8,9,10,11,11-heptachloro-4-oxatetracyclo[6.2.1.02,7.03,5]undec-9-ene Chemical compound ClC1=C(Cl)[C@]2(Cl)[C@H]3[C@@H]4O[C@@H]4[C@H](Cl)[C@H]3[C@@]1(Cl)C2(Cl)Cl ZXFXBSWRVIQKOD-AQTZKLSLSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical compound C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 description 1
• WBEJYOJJBDISQU-UHFFFAOYSA-N 1,2-Dibromo-3-chloropropane Chemical compound ClCC(Br)CBr WBEJYOJJBDISQU-UHFFFAOYSA-N 0.000 description 1
• 229940100682 1,2-dibromo-3-chloropropane Drugs 0.000 description 1
• OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 description 1
• OEVVKKAVYQFQNV-UHFFFAOYSA-N 1-ethenyl-2,4-dimethylbenzene Chemical compound CC1=CC=C(C=C)C(C)=C1 OEVVKKAVYQFQNV-UHFFFAOYSA-N 0.000 description 1
• NVZWEEGUWXZOKI-UHFFFAOYSA-N 1-ethenyl-2-methylbenzene Chemical compound CC1=CC=CC=C1C=C NVZWEEGUWXZOKI-UHFFFAOYSA-N 0.000 description 1
• JZHGRUMIRATHIU-UHFFFAOYSA-N 1-ethenyl-3-methylbenzene Chemical compound CC1=CC=CC(C=C)=C1 JZHGRUMIRATHIU-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• QEDJMOONZLUIMC-UHFFFAOYSA-N 1-tert-butyl-4-ethenylbenzene Chemical compound CC(C)(C)C1=CC=C(C=C)C=C1 QEDJMOONZLUIMC-UHFFFAOYSA-N 0.000 description 1
• HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
• OVSKIKFHRZPJSS-DOMIDYPGSA-N 2-(2,4-dichlorophenoxy)acetic acid Chemical compound OC(=O)[14CH2]OC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-DOMIDYPGSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
• WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
• RUMACXVDVNRZJZ-UHFFFAOYSA-N 2-methylpropyl 2-methylprop-2-enoate Chemical compound CC(C)COC(=O)C(C)=C RUMACXVDVNRZJZ-UHFFFAOYSA-N 0.000 description 1
• CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
• UNRDNFBAJALSEY-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl benzoate Chemical compound C=CC(=O)OCCOC(=O)C1=CC=CC=C1 UNRDNFBAJALSEY-UHFFFAOYSA-N 0.000 description 1
• FSCWZHGZWWDELK-UHFFFAOYSA-N 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione Chemical compound O=C1C(C)(C=C)OC(=O)N1C1=CC(Cl)=CC(Cl)=C1 FSCWZHGZWWDELK-UHFFFAOYSA-N 0.000 description 1
• JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• ZPTVNYMJQHSSEA-UHFFFAOYSA-N 4-nitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1 ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 1
• NTDQQZYCCIDJRK-UHFFFAOYSA-N 4-octylphenol Chemical compound CCCCCCCCC1=CC=C(O)C=C1 NTDQQZYCCIDJRK-UHFFFAOYSA-N 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
• 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• 108010008629 CA-125 Antigen Proteins 0.000 description 1
• 102000007269 CA-125 Antigen Human genes 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 229920000298 Cellophane Polymers 0.000 description 1
• 229920002160 Celluloid Polymers 0.000 description 1
• 102000010792 Chromogranin A Human genes 0.000 description 1
• 108010038447 Chromogranin A Proteins 0.000 description 1
• 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 description 1
• 101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 235000019750 Crude protein Nutrition 0.000 description 1
• 239000005946 Cypermethrin Substances 0.000 description 1
• 101150097493 D gene Proteins 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 1
• VOWAEIGWURALJQ-UHFFFAOYSA-N Dicyclohexyl phthalate Chemical group C=1C=CC=C(C(=O)OC2CCCCC2)C=1C(=O)OC1CCCCC1 VOWAEIGWURALJQ-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101710099240 Elastase-1 Proteins 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 101710198144 Endopolygalacturonase I Proteins 0.000 description 1
• JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000002090 Fibronectin type III Human genes 0.000 description 1
• 108050009401 Fibronectin type III Proteins 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 241000251152 Ginglymostoma cirratum Species 0.000 description 1
• 108010089792 Hemeproteins Proteins 0.000 description 1
• 102000008015 Hemeproteins Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 102000019298 Lipocalin Human genes 0.000 description 1
• 108050006654 Lipocalin Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000005949 Malathion Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 239000005802 Mancozeb Substances 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 239000005583 Metribuzin Substances 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 102000016349 Myosin Light Chains Human genes 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 1
• RUYUCCQRWINUHE-UHFFFAOYSA-N Octachlorostyrene Chemical compound ClC(Cl)=C(Cl)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl RUYUCCQRWINUHE-UHFFFAOYSA-N 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• VWGNQYSIWFHEQU-IBAUKUMTSA-N Oxychlordane Chemical compound ClC1=C(Cl)[C@]2(Cl)C3C(Cl)C4(Cl)OC4C3[C@@]1(Cl)C2(Cl)Cl VWGNQYSIWFHEQU-IBAUKUMTSA-N 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 239000004642 Polyimide Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
• 101710191566 Probable endopolygalacturonase I Proteins 0.000 description 1
• 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 101710149136 Protein Vpr Proteins 0.000 description 1
• 101710086988 Protein terminus Proteins 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 238000001069 Raman spectroscopy Methods 0.000 description 1
• 229920000297 Rayon Polymers 0.000 description 1
• 206010038111 Recurrent cancer Diseases 0.000 description 1
• 206010039020 Rhabdomyolysis Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 239000006087 Silane Coupling Agent Substances 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000006180 TBST buffer Substances 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 102100036407 Thioredoxin Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229910010413 TiO 2 Inorganic materials 0.000 description 1
• CRPUJAZIXJMDBK-UHFFFAOYSA-N Toxaphene Natural products C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 1
• 102000004903 Troponin Human genes 0.000 description 1
• 108090001027 Troponin Proteins 0.000 description 1
• 102000013534 Troponin C Human genes 0.000 description 1
• 102000013394 Troponin I Human genes 0.000 description 1
• 108010065729 Troponin I Proteins 0.000 description 1
• 102000004987 Troponin T Human genes 0.000 description 1
• 108090001108 Troponin T Proteins 0.000 description 1
• 102220595616 Unconventional myosin-XVIIIb_G44E_mutation Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 108010051583 Ventricular Myosins Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
• QROGIFZRVHSFLM-QHHAFSJGSA-N [(e)-prop-1-enyl]benzene Chemical compound C\C=C\C1=CC=CC=C1 QROGIFZRVHSFLM-QHHAFSJGSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 108010063628 acarboxyprothrombin Proteins 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• XCSGPAVHZFQHGE-UHFFFAOYSA-N alachlor Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl XCSGPAVHZFQHGE-UHFFFAOYSA-N 0.000 description 1
• QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
• HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
• 239000012670 alkaline solution Substances 0.000 description 1
• XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
• CSDREXVUYHZDNP-UHFFFAOYSA-N alumanylidynesilicon Chemical compound [Al].[Si] CSDREXVUYHZDNP-UHFFFAOYSA-N 0.000 description 1
• 229910000323 aluminium silicate Inorganic materials 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
• QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 1
• 229910001864 baryta Inorganic materials 0.000 description 1
• RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
• GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
• BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 229910021393 carbon nanotube Inorganic materials 0.000 description 1
• 239000002041 carbon nanotube Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 238000002144 chemical decomposition reaction Methods 0.000 description 1
• 238000012824 chemical production Methods 0.000 description 1
• 238000005229 chemical vapour deposition Methods 0.000 description 1
• BIWJNBZANLAXMG-YQELWRJZSA-N chloordaan Chemical compound ClC1=C(Cl)[C@@]2(Cl)C3CC(Cl)C(Cl)C3[C@]1(Cl)C2(Cl)Cl BIWJNBZANLAXMG-YQELWRJZSA-N 0.000 description 1
• LHHGDZSESBACKH-UHFFFAOYSA-N chlordecone Chemical compound ClC12C3(Cl)C(Cl)(Cl)C4(Cl)C2(Cl)C2(Cl)C4(Cl)C3(Cl)C1(Cl)C2=O LHHGDZSESBACKH-UHFFFAOYSA-N 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 239000002734 clay mineral Substances 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• KBLWLMPSVYBVDK-UHFFFAOYSA-N cyclohexyl prop-2-enoate Chemical compound C=CC(=O)OC1CCCCC1 KBLWLMPSVYBVDK-UHFFFAOYSA-N 0.000 description 1
• 229960005424 cypermethrin Drugs 0.000 description 1
• KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000000151 deposition Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000010612 desalination reaction Methods 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• ZDLVUKNLGUZMAS-UHFFFAOYSA-N dibutyl hydrogen phosphate;ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C.CCCCOP(O)(=O)OCCCC ZDLVUKNLGUZMAS-UHFFFAOYSA-N 0.000 description 1
• BCJAMGWKHPTZEU-UHFFFAOYSA-N dibutyl hydrogen phosphate;ethyl prop-2-enoate Chemical compound CCOC(=O)C=C.CCCCOP(O)(=O)OCCCC BCJAMGWKHPTZEU-UHFFFAOYSA-N 0.000 description 1
• JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
• VFAWCJZNIUIZOC-UHFFFAOYSA-N diethyl hydrogen phosphate;ethyl prop-2-enoate Chemical compound CCOC(=O)C=C.CCOP(O)(=O)OCC VFAWCJZNIUIZOC-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• ZKHFUIIZFCSYQB-UHFFFAOYSA-N dimethyl hydrogen phosphate;ethyl prop-2-enoate Chemical compound CCOC(=O)C=C.COP(O)(=O)OC ZKHFUIIZFCSYQB-UHFFFAOYSA-N 0.000 description 1
• 150000002013 dioxins Chemical class 0.000 description 1
• HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 210000004177 elastic tissue Anatomy 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 230000005611 electricity Effects 0.000 description 1
• 231100000507 endocrine disrupting Toxicity 0.000 description 1
• 108010092028 endopolygalacturonase II Proteins 0.000 description 1
• RDYMFSUJUZBWLH-SVWSLYAFSA-N endosulfan Chemical compound C([C@@H]12)OS(=O)OC[C@@H]1[C@]1(Cl)C(Cl)=C(Cl)[C@@]2(Cl)C1(Cl)Cl RDYMFSUJUZBWLH-SVWSLYAFSA-N 0.000 description 1
• DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 208000028991 esophageal small cell neuroendocrine carcinoma Diseases 0.000 description 1
• 238000005530 etching Methods 0.000 description 1
• MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
• GFJVXXWOPWLRNU-UHFFFAOYSA-N ethenyl formate Chemical compound C=COC=O GFJVXXWOPWLRNU-UHFFFAOYSA-N 0.000 description 1
• UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
• SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000003574 free electron Substances 0.000 description 1
• JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
• 210000004051 gastric juice Anatomy 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229960001269 glycine hydrochloride Drugs 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
• 150000004820 halides Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• PBZROIMXDZTJDF-UHFFFAOYSA-N hepta-1,6-dien-4-one Chemical compound C=CCC(=O)CC=C PBZROIMXDZTJDF-UHFFFAOYSA-N 0.000 description 1
• FRCCEHPWNOQAEU-UHFFFAOYSA-N heptachlor Chemical compound ClC1=C(Cl)C2(Cl)C3C=CC(Cl)C3C1(Cl)C2(Cl)Cl FRCCEHPWNOQAEU-UHFFFAOYSA-N 0.000 description 1
• CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 description 1
• LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
• LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 229910003480 inorganic solid Inorganic materials 0.000 description 1
• 238000012966 insertion method Methods 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229910052622 kaolinite Inorganic materials 0.000 description 1
• 201000011061 large intestine cancer Diseases 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000031700 light absorption Effects 0.000 description 1
• 229960002809 lindane Drugs 0.000 description 1
• 238000001459 lithography Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 229960000453 malathion Drugs 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
• FOXFZRUHNHCZPX-UHFFFAOYSA-N metribuzin Chemical compound CSC1=NN=C(C(C)(C)C)C(=O)N1N FOXFZRUHNHCZPX-UHFFFAOYSA-N 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000002715 modification method Methods 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000003680 myocardial damage Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000002086 nanomaterial Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000002070 nanowire Substances 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 206010061311 nervous system neoplasm Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000004412 neuroendocrine cell Anatomy 0.000 description 1
• 125000004999 nitroaryl group Chemical group 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• HILCQVNWWOARMT-UHFFFAOYSA-N non-1-en-3-one Chemical compound CCCCCCC(=O)C=C HILCQVNWWOARMT-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000004745 nonwoven fabric Substances 0.000 description 1
• LKEDKQWWISEKSW-UHFFFAOYSA-N nonyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCOC(=O)C(C)=C LKEDKQWWISEKSW-UHFFFAOYSA-N 0.000 description 1
• MDYPDLBFDATSCF-UHFFFAOYSA-N nonyl prop-2-enoate Chemical compound CCCCCCCCCOC(=O)C=C MDYPDLBFDATSCF-UHFFFAOYSA-N 0.000 description 1
• SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
• ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 238000000059 patterning Methods 0.000 description 1
• UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical class C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• GYDSPAVLTMAXHT-UHFFFAOYSA-N pentyl 2-methylprop-2-enoate Chemical compound CCCCCOC(=O)C(C)=C GYDSPAVLTMAXHT-UHFFFAOYSA-N 0.000 description 1
• ULDDEWDFUNBUCM-UHFFFAOYSA-N pentyl prop-2-enoate Chemical compound CCCCCOC(=O)C=C ULDDEWDFUNBUCM-UHFFFAOYSA-N 0.000 description 1
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 229960000490 permethrin Drugs 0.000 description 1
• RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 238000000206 photolithography Methods 0.000 description 1
• 238000005240 physical vapour deposition Methods 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
• 229920001721 polyimide Polymers 0.000 description 1
• 229920006254 polymer film Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 230000000379 polymerizing effect Effects 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000005033 polyvinylidene chloride Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• BOQSSGDQNWEFSX-UHFFFAOYSA-N propan-2-yl 2-methylprop-2-enoate Chemical compound CC(C)OC(=O)C(C)=C BOQSSGDQNWEFSX-UHFFFAOYSA-N 0.000 description 1
• LYBIZMNPXTXVMV-UHFFFAOYSA-N propan-2-yl prop-2-enoate Chemical compound CC(C)OC(=O)C=C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 1
• NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 1
• PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
• 238000002331 protein detection Methods 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 239000002964 rayon Substances 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000016150 regulation of muscle contraction Effects 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 102200109792 rs1553255521 Human genes 0.000 description 1
• 102220201545 rs886041401 Human genes 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000005488 sandblasting Methods 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 238000001338 self-assembly Methods 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 239000010944 silver (metal) Substances 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000004381 surface treatment Methods 0.000 description 1
• 239000012756 surface treatment agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 101150047061 tag-72 gene Proteins 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 1
• ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• OEJNXTAZZBRGDN-UHFFFAOYSA-N toxaphene Chemical compound ClC1C(Cl)C2(Cl)C(CCl)(CCl)C(=C)C1(Cl)C2(Cl)Cl OEJNXTAZZBRGDN-UHFFFAOYSA-N 0.000 description 1
• ZXFXBSWRVIQKOD-UHFFFAOYSA-N trans-heptachlor epoxide Natural products ClC1=C(Cl)C2(Cl)C3C4OC4C(Cl)C3C1(Cl)C2(Cl)Cl ZXFXBSWRVIQKOD-UHFFFAOYSA-N 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• FUSUHKVFWTUUBE-UHFFFAOYSA-N vinyl methyl ketone Natural products CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000002023 wood Substances 0.000 description 1